|
A double-blind, 12-month,
placebo- and active-controlled study enrolled immunocompetent adults
with a history of 6 or more recurrences per year. Outcomes for
the overall study population are shown in Table 1.
| Table
1. Recurrence Rates in Immunocompetent Adults at 6 and 12
Months |
| |
6 Months |
12 Months |
| Treatment
Arm |
VALTREX
1 gram
q.d.
(n = 269)
|
ZOVIRAX
400 mg
b.i.d.
(n = 267)
|
Placebo
(n = 134)
|
VALTREX
1 gram
q.d.
(n = 269)
|
ZOVIRAX
400 mg
b.i.d.
(n = 267)
|
Placebo
(n = 134)
|
| Recurrence
free |
55% |
54% |
7% |
34% |
34% |
4% |
| Recurrences |
35% |
36% |
83% |
46% |
46% |
85% |
| Unknowns* |
10% |
10% |
10% |
19% |
19% |
10% |
*Includes lost to follow-up,
discontinuations due to adverse events, and consent withdrawn.
Subjects with 9 or fewer
recurrences per year showed comparable results with VALTREX 500 mg
once daily.
*taken from the official pdr
info on valtrex as of 6/1/07
Thanks, Grace.
|